Gilead Sciences (GILD) Change in Accured Expenses (2009 - 2026)

Gilead Sciences (GILD) has reported Change in Accured Expenses for 18 consecutive years, with -$702.0 million the latest figure, recorded in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$702.0 million, down 187.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$452.0 million (down 1258.97% YoY), and the FY2025 annual result was $6.0 million, down 94.44% from the prior year.
• Change in Accured Expenses was -$702.0 million for Q1 2026 at Gilead Sciences, down from -$395.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $811.0 million in Q3 2025 and troughed at -$1.7 billion in Q1 2022.
• Average Change in Accured Expenses over 5 years is -$53.2 million, with a median of $50.0 million recorded in 2023.
• Year-over-year, Change in Accured Expenses soared 1348.0% in 2022 and tumbled 229.51% in 2025.
• Over 5 years, Change in Accured Expenses stood at $356.0 million in 2022, then declined by 10.96% to $317.0 million in 2023, then fell by 3.79% to $305.0 million in 2024, then sank by 229.51% to -$395.0 million in 2025, then plunged by 77.72% to -$702.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$702.0 million in Q1 2026, -$395.0 million in Q4 2025, and $811.0 million in Q3 2025.